On Monday analysts at Jefferies boosted its price target and estimates on pharmaceutical company AbbVie Inc (ABBV) as various drugs, such as Humira, continue to perform well.
The analysts increased earning estimates on ABBV and now see shares reaching $45, which suggests a +21% upside to Friday’s closing price. The firm maintained a “Buy” rating on AbbVie.
AbbVie shares were down 58 cents, or -1.56%, during pre-market trading on Monday. The stock is up +8.84% since it was spun off from Abbot Labs in early January 2013.
The Bottom Line
Shares of AbbVie (ABBV) have a dividend yield of 4.30% based on Friday’s closing price of $37.18.
AbbVie Inc (ABBV) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.